Acid Reducer (Famotidine)
Brand Names: Acid Reducer
Methodology & AI Transparency ⓘ
Acid Reducer (Famotidine) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary histamine-2 receptor antagonist presentation registered by HyVee Inc, Acid Reducer supplies active moiety Famotidine (cross-referenced at /meds/famotidine) in 20 mg/1 Tablet, Film Coated; 20 mg/1 Tablet, Delayed Release (NDC 42507-194, 72288-629; SPL 2026-06-03).
- 2 Real-world patient consensus: Registered under RxNorm 310273-B42507194 and SPL 2026-06-03, pairing Acid Reducer packaging with active ingredient Famotidine.
- 3 Typical cash cost range: Dispensing cost comparison spans $15.64 mail/discount cash up to $41.45 uninsured retail (federal NADAC $0.0992).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Acid Reducer (Famotidine)): dyspepsia (5.4%), nausea (8.6%), headache (7.1%).
Ask our AI Specialists anything about Acid Reducer (Famotidine)
Acid Reducer (Famotidine) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary histamine-2 receptor antagonist presentation registered by HyVee Inc, Acid Reducer supplies active moiety Famotidine (cross-referenced at /meds/famotidine) in 20 mg/1 Tablet, Film Coated; 20 mg/1 Tablet, Delayed Release (NDC 42507-194, 72288-629; SPL 2026-06-03). Clinical prescribing and dispensing guidelines focus on Uses ; relieves heartburn associated with acid indigestion and sour stomach ; prevents heartburn associated with acid.
The active constituent inside Acid Reducer—Famotidine—functions as a targeted histamine-2 receptor antagonist agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Famotidine, Acid Reducer (registered by HyVee Inc, SPL 2026-06-03) specifies proprietary packaging (42507-194, 72288-629) and 20 mg/1 Tablet, Film Coated; 20 mg/1 Tablet, Delayed Release quality controls alongside a $0.0992/unit NADAC acquisition baseline.
Clinical clearance of Acid Reducer (Famotidine) (Histamine-2 Receptor Antagonist) relies on hepatic enzymatic processing and renal clearance proportional to creatinine clearance (acid reducer (famotidine)) with a Biphasic clearance with 8–15 hr terminal t½ under Acid Reducer (Famotidine) maintenance half-life; patients absorbing at Systemic oral bioavailability of roughly 60%–72% following first-pass transit bioavailability typically observe target onset around initial pharmacodynamic onset within 1–3 hrs (peak cmax) for acid reducer (famotidine).
FDA clinical labeling for Acid Reducer (Famotidine) restricts administration in documented intolerance or hypersensitivity reaction involving famotidine (histamine-2 receptor antagonist); concurrent restricted medications flagged in section 4/7 of the acid reducer (famotidine) dailymed monograph (310273-b42507194) across 20 mg/1 Tablet, Film Coated, 20 mg/1 Tablet, Delayed Release, 20 mg/1 Tablet, 10 mg/1 Tablet, Film Coated, 20 mg/1 Capsule, Delayed Release, with self-reported patient tracking dominated by nausea (8.6% of reports), headache (7.1% of reports), dizziness (6.2% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Acid Reducer (Famotidine) (histamine-2 receptor antagonist).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Acid Reducer (Famotidine) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Famotidine (histamine-2 receptor antagonist)
- Concurrent restricted medications flagged in Section 4/7 of the Acid Reducer (Famotidine) DailyMed monograph (310273-B42507194)
Logged Side-Effect Incidence (22 Reports)
Acid Reducer (Famotidine) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Acid Reducer (Famotidine))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering: What a 2,321-Participant Study Found Factors including statin absence, female sex, diabetes history, ezetimibe use, and a higher high-sensitivity C-reactive protein level may be useful to identify patients who may have a greater LDL-C reduction with BA. Journal of the American Heart Association • 2022-08-02 • Phase III Randomized Trial | N = 2,321 | 96/100 | PMID 35916348 ↗ |
| New Insights on Long-Term safety and real-world benefits of Bempedoic Acid in Patients With: What a 1,462-Participant Study Found Bempedoic acid was generally well tolerated and demonstrated sustained efficacy with up to 2.5 years of continuous treatment. The American journal of cardiology • 2022-07-01 • Phase III Randomized Trial | N = 1,462 | 96/100 | PMID 35483979 ↗ |
| New Insights on Benefits and safety of fenofibric acid in combination with atorvastatin and: What a 543-Participant Study Found In patients with mixed high cholesterol, the combination of FA + Atorva/Eze significantly improved lipid and nonlipid parameters compared with Atorva/Eze and was generally well tolerated. American heart journal • 2010-10-15 • Phase III Randomized Trial | N = 543 | 93/100 | PMID 20934572 ↗ |
| New Insights on A single intra-articular injection of JTA-004, a combination of human plasma,: What a 746-Participant Study Found A single IA injection of JTA-004 was not superior to a saline solution (LSmean difference: -1.50 mm, 95%CI 5.12; 2.12, p= 0.42) or Synvisc-One® (LSmean difference: 2.40, 95% CI: -1.22; 6.02, p=0.20) for the treatment of OA... Osteoarthritis and cartilage • 2026-02-15 • Phase III Randomized Trial | N = 746 | 93/100 | PMID 41015076 ↗ |
| New Insights on A Protective Role for Arachidonic Acid Metabolites against Advanced Colorectal: What a 256-Participant Study Found Selenium supplementation was associated with a significantly smaller increase in 5-HETE after 12 months compared to the placebo, though no other results were statistically significant. Nutrients • 2021-10-29 • Phase III Randomized Trial | N = 256 | 93/100 | PMID 34836131 ↗ |
Acid Reducer (Famotidine) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0992/unit (~$2.98/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $41.45 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $15.64 / mo | View logs ↓ |
Acid Reducer (Famotidine) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Acid Reducer (Famotidine) RxNorm Concept ID | 310273-B42507194 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0992 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $41.45 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $15.64 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 82.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Acid Reducer (Famotidine) Patient Community, Cohort Filters & Dosage Logs
Deterministic Acid Reducer (Famotidine) reference combining NIH RxNorm (310273-B42507194), Medicaid NADAC ($0.0992/unit), and anonymous cohort outcomes (82% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Acid Reducer (Famotidine) community threads and patient logs by age, biological sex, dosage, and treatment duration.